An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer

An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancer

This randomized, open-label, active-controlled study investigated the safety and efficacy of three doses of Rolontis (eflapegrastim), a novel, long-acting myeloid growth factor, versus pegfilgrastim in breast cancer patients being treated with docetaxel and cyclophosphamide (TC). The primary efficac...

Full description

Bibliographic Details
Main Authors: Vacirca, J., Chan, Arlene, Mezei, K., Adoo, C., Pápai, Z., Mcgregor, K., Okera, M., Horváth, Z., Landherr, L., Hanslik, J., Hager, S., Ibrahim, E., Rostom, M., Bhat, G., Choi, M., Reddy, G., Tedesco, K., Agajanian, R., Láng, I., Schwartzberg, L.
Format: Journal Article
Published: 2018
Online Access:http://hdl.handle.net/20.500.11937/66626

Internet

http://hdl.handle.net/20.500.11937/66626

Similar Items